Literature DB >> 11138777

Platelet-derived CXC chemokines: old players in new games.

E Brandt1, A Ludwig, F Petersen, H D Flad.   

Abstract

Although platelet factor 4 (PF-4) and the beta-thromboglobulin (beta-TG) proteins represent the first chemokines to be discovered, their functional roles in host defense became clear only recently. Residing in platelets as storage proteins and becoming released into the blood at very high concentrations, these mediators appear to fulfill different and complementary tasks as first-line mediators in the recruitment and activation of leukocytes, as well in the regulation of tissue repair. Whereas both proteins are structurally closely related members of the CXC chemokine subfamily, they are subject to quite dissimilar regulatory mechanisms controlling their generation and their spectrum of biological activities. Thus, proteolytic processing of inactive precursors plays a decisive role in whether the beta-TG proteins will act as stimulatory or inhibitory agents in neutrophil activation via the G protein-coupled receptors CXCR-1 and 2. PF-4, existing as a single molecular form, is largely resistant to proteolytic modification, but its interaction with an unusual receptor(s) on leukocytes (a proteoglycan) appears to depend on its oligomeric state. There is growing evidence that both chemokines may interfere with each other at various regulatory levels to promote coordinated cell activation. Moreover, recent findings suggest novel and unexpected activities for these chemokines, which may extend our view on early host defense.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138777     DOI: 10.1034/j.1600-065x.2000.17705.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  38 in total

Review 1.  Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense.

Authors:  Manuela Dürr; Andreas Peschel
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Internalization of IgG-coated targets results in activation and secretion of soluble CD40 ligand and RANTES by human platelets.

Authors:  Adam J Antczak; Joshua A Vieth; Navinderjit Singh; Randall G Worth
Journal:  Clin Vaccine Immunol       Date:  2010-12-22

3.  Monocyte-derived CXCL7 peptides in the marrow microenvironment.

Authors:  Manoj M Pillai; Mineo Iwata; Norihiro Awaya; Lynn Graf; Beverly Torok-Storb
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

Review 4.  Platelet-derived chemokines: pathophysiology and therapeutic aspects.

Authors:  Hans-Dieter Flad; Ernst Brandt
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

Review 5.  Platelet "first responders" in wound response, cancer, and metastasis.

Authors:  David G Menter; Scott Kopetz; Ernest Hawk; Anil K Sood; Jonathan M Loree; Paolo Gresele; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

6.  Impact of chemokines CCR5∆32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population.

Authors:  Vibha Singh; Praveen Kumar Jaiswal; Rohit Kapoor; Rakesh Kapoor; Rama Devi Mittal
Journal:  Tumour Biol       Date:  2014-01-16

Review 7.  Platelets in Pulmonary Immune Responses and Inflammatory Lung Diseases.

Authors:  Elizabeth A Middleton; Andrew S Weyrich; Guy A Zimmerman
Journal:  Physiol Rev       Date:  2016-08-03       Impact factor: 37.312

8.  CXCL7-Mediated Stimulation of Lymphangiogenic Factors VEGF-C, VEGF-D in Human Breast Cancer Cells.

Authors:  Minghuan Yu; Richard Berk; Mary Ann Kosir
Journal:  J Oncol       Date:  2010-06-22       Impact factor: 4.375

9.  Intramedullary megakaryocytes internalize released platelet factor 4 and store it in alpha granules.

Authors:  M P Lambert; R Meng; L Xiao; D C Harper; M S Marks; M A Kowalska; M Poncz
Journal:  J Thromb Haemost       Date:  2015-09-29       Impact factor: 5.824

10.  Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.

Authors:  Michele P Lambert; Lubica Rauova; Matthew Bailey; Martha C Sola-Visner; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.